The worldwide market for respiratory drugs is expanding due to the prevalence of conditions like asthma, idiopathic pulmonary fibrosis (IPF), and respiratory tract infections (RTI) across the globe. Among these, COPD stands out as a significant challenge and ranks as the third leading cause of death globally, underscoring the critical demand for innovation in this field.

We specialize in managing trials across both innovative and generic products, including drugs, medical devices, and in vitro diagnostics for respiratory diseases.

Our comprehensive services encompass the entire product lifecycle—from developing clinical development plans and navigating pre-clinical stages to conducting Phase I-III trials, post-marketing Phase IV studies, and pharmacovigilance. We employ innovative monitoring techniques and visual analytics to ensure the delivery of high-quality data critical to advancing your respiratory therapy.

Led by a team with deep expertise in respiratory clinical settings and patient profiles, we facilitate seamless connections with hospitals and outpatient facilities. This approach accelerates trial initiation and ensures you achieve the actionable results necessary for success. Learn more about Ojha Institute of Chest Diseases.